Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) has received a consensus rating of “Hold” from the six research firms that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold rating. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $2.32.
Several equities analysts have commented on CARA shares. HC Wainwright downgraded shares of Cara Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, June 13th. Canaccord Genuity Group restated a “hold” rating and issued a $1.00 target price (down previously from $10.00) on shares of Cara Therapeutics in a research note on Thursday, June 13th. Canaccord Genuity Group downgraded shares of Cara Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $10.00 to $1.00 in a research note on Thursday, June 13th. Needham & Company LLC cut Cara Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, June 13th. Finally, Stifel Nicolaus downgraded Cara Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $6.00 to $1.00 in a research note on Thursday, June 13th.
Read Our Latest Research Report on CARA
Institutional Trading of Cara Therapeutics
Cara Therapeutics Price Performance
Shares of NASDAQ CARA opened at $0.30 on Friday. Cara Therapeutics has a 1-year low of $0.24 and a 1-year high of $1.87. The business has a 50-day moving average of $0.34 and a 200-day moving average of $0.55. The company has a market capitalization of $16.51 million, a price-to-earnings ratio of -0.13 and a beta of 0.70.
Cara Therapeutics (NASDAQ:CARA – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.10). The firm had revenue of $0.99 million for the quarter, compared to analyst estimates of $1.26 million. Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. Research analysts expect that Cara Therapeutics will post -1.24 EPS for the current fiscal year.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Featured Articles
- Five stocks we like better than Cara Therapeutics
- What Investors Need to Know to Beat the Market
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- How to Start Investing in Real Estate
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Following Congress Stock Trades
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.